Text Size: A A A      Contrast:        Transparency in Coverage Rule
 

Inclusive Research Brings New Possibilities Into Sight

 

“…Genentech developed and launched the Elevatum clinical trial, the first company-sponsored retinal study of its kind. The trial was designed specifically to study DME in underrepresented populations… The Phase IV study began enrolling patients in early 2022 and includes patients who identify as Black, African American, Hispanic, LatinX, Native American, Alaska Native, Native Hawaiian or Pacific Islander…”

 

Joseph Coney, MD, of Retina Associates of Cleveland, is a lead investigator of the Elevatum trial and shared his thoughts on the study: “As a Black ophthalmologist, it’s deeply meaningful for me to participate in a trial that’s focused on communities of color in a way that no other trial has in ophthalmology. And my hope is it opens the door for others to follow suit.”

 

Elevatum study description:

A Phase IV, multicenter, open-label, single-arm study designed to investigate treatment response in treatment-naïve, underrepresented (Black/African American, Hispanic/Latino American, or Native American/Alaskan Hawaiian or other Pacific Islander) adult patients with diabetic macular edema (DME) who are treated with Faricimab (6 mg). 

 

More details about this study can be found on our website, https://www.retina-doctors.com/research-trials/clinical-trials/list-of-clinical-trials under studies for Diabetic Retinopathy.

 

General information about the ELEVATUM study can be found from the ClinicalTrials.gov website << A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema - Full Text View - ClinicalTrials.gov>>